Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Michael Bristow to Heart Failure

This is a "connection" page, showing publications Michael Bristow has written about Heart Failure.

 
Connection Strength
  
 
 
13.415
  
  1. Carroll IA, Piccini JP, Steinberg BA, Tzou WS, Richards JC, DeMets DL, Bristow MR. Symptoms Burden as a Clinical Outcomes Assessment in Heart?Failure Patients With Atrial Fibrillation. JACC Heart Fail. 2025 Apr; 13(4):573-585.
    View in: PubMed
    Score: 0.367
  2. Dimond MG, Fiuzat M, Mentz RJ, Lala-Trindade A, Whellan DJ, Walsh MN, Costanzo MR, Yehya A, Desvigne-Nickens P, Malik F, O'Connor CM, Bristow MR. Rewarding Site-Based Research: A Step Toward Improving the Ecosystem of?Heart?Failure Clinical Trials. JACC Heart Fail. 2024 01; 12(1):226-228.
    View in: PubMed
    Score: 0.339
  3. Doran B, Mei C, Varosy PD, Kao DP, Saxon LA, Feldman AM, DeMets D, Bristow MR. The Addition of a Defibrillator to?Resynchronization Therapy Decreases?Mortality in Patients With Nonischemic Cardiomyopathy. JACC Heart Fail. 2021 06; 9(6):439-449.
    View in: PubMed
    Score: 0.287
  4. O'Connor CM, Bristow MR. Changing U.S. Heart Failure Research Culture: Part 2-Recognizing Frontline Investigators and Coordinators. JACC Heart Fail. 2020 12; 8(12):1050-1051.
    View in: PubMed
    Score: 0.278
  5. Sucharov CC, Nakano SJ, Slavov D, Schwisow JA, Rodriguez E, Nunley K, Medway A, Stafford N, Nelson P, McKinsey TA, Movsesian M, Minobe W, Carroll IA, Taylor MRG, Bristow MR. A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium. J Am Coll Cardiol. 2019 03 19; 73(10):1173-1184.
    View in: PubMed
    Score: 0.247
  6. Shamoun F, De Marco T, DeMets D, Mei C, Lindenfeld J, Saxon LA, Boehmer JP, Leigh J, Yong P, Feldman AM, Bristow MR. Impact of Degree of Left Ventricular Remodeling on Clinical Outcomes From Cardiac Resynchronization Therapy. JACC Heart Fail. 2019 04; 7(4):281-290.
    View in: PubMed
    Score: 0.246
  7. Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF, Felker GM, Liggett SB, O'Connor CM, Bristow MR. Dose Response of ?-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med. 2018 08; 11(8):e002210.
    View in: PubMed
    Score: 0.237
  8. O'Connor CM, Bristow MR. Changing the Research Culture in the United States. JACC Heart Fail. 2018 Apr; 6(4):344-345.
    View in: PubMed
    Score: 0.231
  9. Piccini JP, Connolly SJ, Abraham WT, Healey JS, Steinberg BA, Al-Khalidi HR, Dignacco P, van Veldhuisen DJ, Sauer WH, White M, Wilton SB, Anand IS, Dufton C, Marshall DA, Aleong RG, Davis GW, Clark RL, Emery LL, Bristow MR. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. Am Heart J. 2018 05; 199:51-58.
    View in: PubMed
    Score: 0.226
  10. Bristow MR, Kao DP, Breathett KK, Altman NL, Gorcsan J, Gill EA, Lowes BD, Gilbert EM, Quaife RA, Mann DL. Structural and Functional Phenotyping of the Failing Heart: Is the Left Ventricular Ejection Fraction Obsolete? JACC Heart Fail. 2017 11; 5(11):772-781.
    View in: PubMed
    Score: 0.225
  11. Leary PJ, Kronmal RA, Bluemke DA, Buttrick PM, Jones KL, Kao DP, Kawut SM, Krieger EV, Lima JA, Minobe W, Ralph DD, Tedford RJ, Weiss NS, Bristow MR. Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial). Am J Cardiol. 2018 01 15; 121(2):256-261.
    View in: PubMed
    Score: 0.224
  12. Bristow MR, Altman NL. Heart Rate in Preserved Ejection?Fraction?Heart Failure. JACC Heart Fail. 2017 11; 5(11):792-794.
    View in: PubMed
    Score: 0.224
  13. Bristow MR. Genetic variation expressed in the brain may impact heart failure. Eur J Heart Fail. 2017 03; 19(3):324-325.
    View in: PubMed
    Score: 0.215
  14. Sucharov CC, Kao DP, Port JD, Karimpour-Fard A, Quaife RA, Minobe W, Nunley K, Lowes BD, Gilbert EM, Bristow MR. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight. 2017 01 26; 2(2):e89169.
    View in: PubMed
    Score: 0.213
  15. Bristow MR, Saxon LA, Feldman AM, Mei C, Anderson SA, DeMets DL. Lessons Learned and Insights Gained in?the?Design, Analysis, and Outcomes of?the COMPANION Trial. JACC Heart Fail. 2016 07; 4(7):521-535.
    View in: PubMed
    Score: 0.204
  16. Taylor MR, Sun AY, Davis G, Fiuzat M, Liggett SB, Bristow MR. Race, common genetic variation, and therapeutic response disparities in heart failure. JACC Heart Fail. 2014 Dec; 2(6):561-72.
    View in: PubMed
    Score: 0.182
  17. Bristow MR. Polymorphic variation in the G-protein beta-3 subunit gene and response to BiDil in A-HeFT: Basis for an African-American pharmacogenetic advantage to nitric oxide donor therapy? JACC Heart Fail. 2014 Dec; 2(6):558-60.
    View in: PubMed
    Score: 0.182
  18. Aleong RG, Sauer WH, Davis G, Bristow MR. New-onset atrial fibrillation predicts heart failure progression. Am J Med. 2014 Oct; 127(10):963-71.
    View in: PubMed
    Score: 0.178
  19. Fiuzat M, O'Connor CM, Gueyffier F, Mascette AM, Geller NL, Mebazaa A, Voors AA, Adams KF, Pi?a IL, Neyses L, Muntendam P, Felker GM, Pitt B, Zannad F, Bristow MR. Biomarker-guided therapies in heart failure: a forum for unified strategies. J Card Fail. 2013 Aug; 19(8):592-9.
    View in: PubMed
    Score: 0.167
  20. Bristow MR, Aleong RG. Treatment of the heart failure patient with atrial fibrillation: a major unmet need. JACC Heart Fail. 2013 Feb; 1(1):29-30.
    View in: PubMed
    Score: 0.162
  21. Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013 Feb; 6(1):137-43.
    View in: PubMed
    Score: 0.161
  22. Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar; 15(3):324-33.
    View in: PubMed
    Score: 0.160
  23. Bristow MR. Pharmacogenetic targeting of drugs for heart failure. Pharmacol Ther. 2012 Apr; 134(1):107-15.
    View in: PubMed
    Score: 0.151
  24. Bristow MR. Treatment of chronic heart failure with ?-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011 Oct 28; 109(10):1176-94.
    View in: PubMed
    Score: 0.148
  25. Fiuzat M, Bristow MR. Pharmacogenetics in heart failure trials. Heart Fail Clin. 2011 Oct; 7(4):553-9.
    View in: PubMed
    Score: 0.147
  26. O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, Gattis-Stough W, Davis GW, Bristow MR. Influence of global region on outcomes in heart failure ?-blocker trials. J Am Coll Cardiol. 2011 Aug 23; 58(9):915-22.
    View in: PubMed
    Score: 0.146
  27. Murphy GA, Fiuzat M, Bristow MR. Targeting heart failure therapeutics: a historical perspective. Heart Fail Clin. 2010 Jan; 6(1):11-23.
    View in: PubMed
    Score: 0.131
  28. Sumner AD, Boehmer JP, Saxon LA, Carson P, Feldman AM, Galle E, Bristow MR. Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy. Congest Heart Fail. 2009 Jul-Aug; 15(4):159-64.
    View in: PubMed
    Score: 0.126
  29. Saxon LA, Olshansky B, Volosin K, Steinberg JS, Lee BK, Tomassoni G, Guarnieri T, Rao A, Yong P, Galle E, Leigh J, Ecklund F, Bristow MR. Influence of left ventricular lead location on outcomes in the COMPANION study. J Cardiovasc Electrophysiol. 2009 Jul; 20(7):764-8.
    View in: PubMed
    Score: 0.123
  30. Anand IS, Carson P, Galle E, Song R, Boehmer J, Ghali JK, Jaski B, Lindenfeld J, O'Connor C, Steinberg JS, Leigh J, Yong P, Kosorok MR, Feldman AM, DeMets D, Bristow MR. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2009 Feb 24; 119(7):969-77.
    View in: PubMed
    Score: 0.123
  31. Movsesian M, Stehlik J, Vandeput F, Bristow MR. Phosphodiesterase inhibition in heart failure. Heart Fail Rev. 2009 Dec; 14(4):255-63.
    View in: PubMed
    Score: 0.122
  32. Sauer WH, Bristow MR. The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial in perspective. J Interv Card Electrophysiol. 2008 Jan; 21(1):3-11.
    View in: PubMed
    Score: 0.113
  33. Metra M, Dei Cas L, Bristow MR. The pathophysiology of acute heart failure--it is a lot about fluid accumulation. Am Heart J. 2008 Jan; 155(1):1-5.
    View in: PubMed
    Score: 0.113
  34. Ghali JK, Boehmer J, Feldman AM, Saxon LA, Demarco T, Carson P, Yong P, Galle EG, Leigh J, Ecklund FL, Bristow MR. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail. 2007 Nov; 13(9):769-73.
    View in: PubMed
    Score: 0.112
  35. Lindenfeld J, Feldman AM, Saxon L, Boehmer J, Carson P, Ghali JK, Anand I, Singh S, Steinberg JS, Jaski B, DeMarco T, Mann D, Yong P, Galle E, Ecklund F, Bristow M. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation. 2007 Jan 16; 115(2):204-12.
    View in: PubMed
    Score: 0.106
  36. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006 Jul 25; 103(30):11288-93.
    View in: PubMed
    Score: 0.103
  37. Lowes BD, Zolty R, Minobe WA, Robertson AD, Leach S, Hunter L, Bristow MR. Serial gene expression profiling in the intact human heart. J Heart Lung Transplant. 2006 May; 25(5):579-88.
    View in: PubMed
    Score: 0.101
  38. Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR. Rationale and design of the enoximone clinical trials program. J Card Fail. 2005 Dec; 11(9):659-69.
    View in: PubMed
    Score: 0.098
  39. Rivera DA, Bristow MR. Cardiac resynchronization--a heart failure perspective. Ann Noninvasive Electrocardiol. 2005 Oct; 10(4 Suppl):16-23.
    View in: PubMed
    Score: 0.097
  40. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005 May 31; 111(21):2837-49.
    View in: PubMed
    Score: 0.095
  41. Bristow MR, Adams KF, Bauman JL, Feldman AM, Giles TD, Goldstein S, Mann DL, Talbert RL. The COMET trial. Congest Heart Fail. 2005 Jan-Feb; 11(1):39-47.
    View in: PubMed
    Score: 0.092
  42. Pittenger B, Gill EA, Holcslaw TL, Bristow MR. Relation of dose of carvedilol to reduction in QT dispersion in patients with mild to moderate heart failure secondary to ischemic or to idiopathic dilated cardiomyopathy. Am J Cardiol. 2004 Dec 01; 94(11):1459-62.
    View in: PubMed
    Score: 0.092
  43. Taylor MR, Bristow MR. The emerging pharmacogenomics of the beta-adrenergic receptors. Congest Heart Fail. 2004 Nov-Dec; 10(6):281-8.
    View in: PubMed
    Score: 0.091
  44. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004 Sep 14; 110(11):1437-42.
    View in: PubMed
    Score: 0.090
  45. Blumer V, Januzzi JL, Lindenfeld J, Solomon SD, Psotka MA, Carson PE, Bristow MR, Abraham WT, Gandotra C, Saville BR, O'Connor C, Fiuzat M. Heart?Failure Drug Development Over?the?Eras: From the Heart?Failure Collaboratory. JACC Heart Fail. 2024 Nov; 12(11):1803-1813.
    View in: PubMed
    Score: 0.089
  46. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20; 350(21):2140-50.
    View in: PubMed
    Score: 0.089
  47. Fleming TR, Wittes J, Fiuzat M, Bristow MR, Rockhold FW, Connor JT, Saville BR, Claggett B, Cavagna I, Abraham WT, Cook TD, Lindenfeld J, O'Connor C, DeMets DL. Training the Next Generation of Data Monitoring Committee Members: An Initiative of the Heart?Failure Collaboratory. JACC Heart Fail. 2024 Aug; 12(8):1317-1327.
    View in: PubMed
    Score: 0.088
  48. Martin TG, Pak H, Gerhard GS, Merali S, Merali C, Lemster B, Dubey P, McTiernan CF, Bristow MR, Feldman AM, Kirk JA. Dysregulated Autophagy and Sarcomere Dysfunction in Patients With Heart Failure With Co-Occurrence of P63A and P380S BAG3 Variants. J Am Heart Assoc. 2023 12 19; 12(24):e029938.
    View in: PubMed
    Score: 0.086
  49. Dimond MG, Ibrahim NE, Fiuzat M, McMurray JJV, Lindenfeld J, Ahmad T, Bozkurt B, Bristow MR, Butler J, Carson PE, Felker GM, Jessup M, Murillo J, Kondo T, Solomon SD, Abraham WT, O'Connor CM, Psotka MA. Left Ventricular Ejection Fraction and the Future of Heart?Failure Phenotyping. JACC Heart Fail. 2024 Mar; 12(3):451-460.
    View in: PubMed
    Score: 0.086
  50. Bristow MR, Feldman AM, Adams KF, Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail. 2003 Dec; 9(6):444-53.
    View in: PubMed
    Score: 0.086
  51. Bristow MR. Microarray measurements of gene expression before and after left ventricular assist device placement. J Am Coll Cardiol. 2003 Apr 02; 41(7):1107-8.
    View in: PubMed
    Score: 0.082
  52. Linseman JV, Bristow MR. Drug therapy and heart failure prevention. Circulation. 2003 Mar 11; 107(9):1234-6.
    View in: PubMed
    Score: 0.081
  53. Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation. 2003 Mar 04; 107(8):1100-2.
    View in: PubMed
    Score: 0.081
  54. Rubino M, Travers JG, Headrick AL, Enyart BT, Lemieux ME, Cavasin MA, Schwisow JA, Hardy EJ, Kaltenbacher KJ, Felisbino MB, Jonas E, Ambardekar AV, Bristow MR, Koch KA, McKinsey TA. Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart. Circ Res. 2023 01 06; 132(1):10-29.
    View in: PubMed
    Score: 0.080
  55. Bristow MR, Long CS. Cardiotrophin-1 in heart failure. Circulation. 2002 Sep 17; 106(12):1430-2.
    View in: PubMed
    Score: 0.079
  56. Felker GM, Buttrick P, Rosenzweig A, Abel ED, Allen LA, Bristow M, Das S, DeVore AD, Drakos SG, Fang JC, Freedman JE, Hernandez AF, Li DY, McKinsey TA, Newton-Cheh C, Rogers JG, Shah RV, Shah SH, Stehlik J, Selzman CH. Heart Failure Strategically Focused Research Network: Summary of Results and Future Directions. J Am Heart Assoc. 2022 09 20; 11(18):e025517.
    View in: PubMed
    Score: 0.079
  57. Zhao Y, Riching AS, Knight WE, Chi C, Broadwell LJ, Du Y, Abdel-Hafiz M, Ambardekar AV, Irwin DC, Proenza C, Xu H, Leinwand LA, Walker LA, Woulfe KC, Bristow MR, Buttrick PM, Song K. Cardiomyocyte-Specific Long Noncoding RNA Regulates Alternative Splicing of the Triadin Gene in the Heart. Circulation. 2022 08 30; 146(9):699-714.
    View in: PubMed
    Score: 0.078
  58. Cleland JGF, Bristow MR, Freemantle N, Olshansky B, Gras D, Saxon L, Tavazzi L, Boehmer J, Ghio S, Feldman AM, Daubert JC, de Mets D. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF. Eur J Heart Fail. 2022 06; 24(6):1080-1090.
    View in: PubMed
    Score: 0.077
  59. Li H, Trager LE, Liu X, Hastings MH, Xiao C, Guerra J, To S, Li G, Yeri A, Rodosthenous R, Silverman MG, Das S, Ambardekar AV, Bristow MR, Gonz?lez-Rosa JM, Rosenzweig A. lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth. Circulation. 2022 04 19; 145(16):1218-1233.
    View in: PubMed
    Score: 0.076
  60. Purmah Y, Cornhill A, Lei LY, Dykstra S, Mikami Y, Satriano A, Labib D, Flewitt J, Rivest S, Sandonato R, Seib M, Howarth AG, Lydell CP, Heydari B, Merchant N, Bristow M, Kolman L, Fine NM, White JA. Mid-wall striae fibrosis predicts heart failure admission, composite heart failure events, and life-threatening arrhythmias in dilated cardiomyopathy. Sci Rep. 2022 02 02; 12(1):1739.
    View in: PubMed
    Score: 0.076
  61. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
    View in: PubMed
    Score: 0.075
  62. Kinugawa K, Long CS, Bristow MR. Expression of TR isoforms in failing human heart. J Clin Endocrinol Metab. 2001 Oct; 86(10):5089-90.
    View in: PubMed
    Score: 0.074
  63. Piccini JP, Dufton C, Carroll IA, Healey JS, Abraham WT, Khaykin Y, Aleong R, Krueger SK, Sauer WH, Wilton SB, Rienstra M, van Veldhuisen DJ, Anand IS, White M, Camm AJ, Ziegler PD, Marshall D, Bristow MR, Connolly SJ. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol. 2021 08; 14(8):e009591.
    View in: PubMed
    Score: 0.073
  64. Leopold JA, Kawut SM, Aldred MA, Archer SL, Benza RL, Bristow MR, Brittain EL, Chesler N, DeMan FS, Erzurum SC, Gladwin MT, Hassoun PM, Hemnes AR, Lahm T, Lima JAC, Loscalzo J, Maron BA, Rosa LM, Newman JH, Redline S, Rich S, Rischard F, Sugeng L, Tang WHW, Tedford RJ, Tsai EJ, Ventetuolo CE, Zhou Y, Aggarwal NR, Xiao L. Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circ Heart Fail. 2021 06; 14(6).
    View in: PubMed
    Score: 0.072
  65. Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents. Curr Cardiol Rep. 2001 May; 3(3):224-31.
    View in: PubMed
    Score: 0.072
  66. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001 May; 33(5):887-905.
    View in: PubMed
    Score: 0.072
  67. Purmah Y, Lei LY, Dykstra S, Mikami Y, Cornhill A, Satriano A, Flewitt J, Rivest S, Sandonato R, Seib M, Lydell CP, Howarth AG, Heydari B, Merchant N, Bristow M, Fine N, Gaztanaga J, White JA. Right Ventricular Ejection Fraction for the Prediction of Major Adverse Cardiovascular and Heart Failure-Related Events: A Cardiac MRI Based Study of 7131 Patients With Known or Suspected Cardiovascular Disease. Circ Cardiovasc Imaging. 2021 03; 14(3):e011337.
    View in: PubMed
    Score: 0.071
  68. Beldhuis IE, Myhre PL, Bristow M, Claggett B, Damman K, Fang JC, Fleg JL, McKinlay S, Lewis EF, O'Meara E, Pitt B, Shah SJ, Vardeny O, Voors AA, Pfeffer MA, Solomon SD, Desai AS. Spironolactone in Patients With Heart?Failure, Preserved Ejection Fraction, and Worsening Renal Function. J Am Coll Cardiol. 2021 03 09; 77(9):1211-1221.
    View in: PubMed
    Score: 0.071
  69. Bristow M. Of phospholamban, mice, and humans with heart failure. Circulation. 2001 Feb 13; 103(6):787-8.
    View in: PubMed
    Score: 0.071
  70. Bhatt AS, Abraham WT, Lindenfeld J, Bristow M, Carson PE, Felker GM, Fonarow GC, Greene SJ, Psotka MA, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Wittes J, Fiuzat M, O'Connor CM, Butler J. Treatment of HF in an Era of Multiple?Therapies: Statement From the HF Collaboratory. JACC Heart Fail. 2021 01; 9(1):1-12.
    View in: PubMed
    Score: 0.070
  71. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000 Nov 14; 102(20 Suppl 4):IV14-23.
    View in: PubMed
    Score: 0.069
  72. Bristow M. Etomoxir: a new approach to treatment of chronic heart failure. Lancet. 2000 Nov 11; 356(9242):1621-2.
    View in: PubMed
    Score: 0.069
  73. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail. 2000 Sep; 6(3):276-85.
    View in: PubMed
    Score: 0.068
  74. Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Greenberg MA, Rahko PS, Dec GW, LeJemtel TH, Roden RL, Schleman MM, Robertson AD, Gorczynski RJ, Bristow MR. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol. 2000 Aug; 36(2):501-8.
    View in: PubMed
    Score: 0.068
  75. Bristow MR. Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail. 2000 Jun; 6(2 Suppl 1):8-14.
    View in: PubMed
    Score: 0.067
  76. Lowes BD, Simon MA, Tsvetkova TO, Bristow MR. Inotropes in the beta-blocker era. Clin Cardiol. 2000 Mar; 23(3 Suppl):III11-6.
    View in: PubMed
    Score: 0.066
  77. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000 Feb 08; 101(5):558-69.
    View in: PubMed
    Score: 0.066
  78. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, Bristow MR. Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J Physiol. 1999 05; 276(5):H1678-90.
    View in: PubMed
    Score: 0.062
  79. Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradovic V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ. Bucindolol for the Maintenance of Sinus?Rhythm in a Genotype-Defined HF?Population: The GENETIC-AF Trial. JACC Heart Fail. 2019 07; 7(7):586-598.
    View in: PubMed
    Score: 0.062
  80. Bristow MR. Mechanisms of development of heart failure in the hypertensive patient. Cardiology. 1999; 92 Suppl 1:3-6; discussion 7-9, 20-1.
    View in: PubMed
    Score: 0.061
  81. Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol. 1998 Dec; 21(12 Suppl 1):I3-13.
    View in: PubMed
    Score: 0.061
  82. Gerdes AM, Onodera T, Tamura T, Said S, Bohlmeyer TJ, Abraham WT, Bristow MR. New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material. J Card Fail. 1998 Dec; 4(4):343-8.
    View in: PubMed
    Score: 0.061
  83. Sweet ME, Cocciolo A, Slavov D, Jones KL, Sweet JR, Graw SL, Reece TB, Ambardekar AV, Bristow MR, Mestroni L, Taylor MRG. Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure. BMC Genomics. 2018 Nov 12; 19(1):812.
    View in: PubMed
    Score: 0.060
  84. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998 May; 31(6):1336-40.
    View in: PubMed
    Score: 0.058
  85. O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM. Improving Heart Failure Therapeutics Development in the United States: The?Heart?Failure?Collaboratory. J Am Coll Cardiol. 2018 01 30; 71(4):443-453.
    View in: PubMed
    Score: 0.057
  86. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. 1998 Jan 15; 81(2):247-50.
    View in: PubMed
    Score: 0.057
  87. Bristow M, Port JD. Beta-adrenergic blockade in chronic heart failure. Scand Cardiovasc J Suppl. 1998; 47:45-55.
    View in: PubMed
    Score: 0.057
  88. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997 Dec 04; 80(11A):26L-40L.
    View in: PubMed
    Score: 0.057
  89. Shah P, Bristow MR, Port JD. MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential. Curr Heart Fail Rep. 2017 12; 14(6):454-464.
    View in: PubMed
    Score: 0.057
  90. Abraham WT, Bristow MR. Specialized centers for heart failure management. Circulation. 1997 Nov 04; 96(9):2755-7.
    View in: PubMed
    Score: 0.056
  91. Kalscheur MM, Saxon LA, Lee BK, Steinberg JS, Mei C, Buhr KA, DeMets DL, Bristow MR, Singh SN. Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trial. Heart Rhythm. 2017 06; 14(6):858-865.
    View in: PubMed
    Score: 0.054
  92. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997 Mar 15; 79(6):794-8.
    View in: PubMed
    Score: 0.054
  93. Asano K, Dutcher DL, Port JD, Minobe WA, Tremmel KD, Roden RL, Bohlmeyer TJ, Bush EW, Jenkin MJ, Abraham WT, Raynolds MV, Zisman LS, Perryman MB, Bristow MR. Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation. 1997 Mar 04; 95(5):1193-200.
    View in: PubMed
    Score: 0.054
  94. Bristow MR, Sharma K, Assmann SF, Linas S, Gersh BJ, Grady C, Rice MM, Singh S, Boineau R, McKinlay SM, Greenberg BH. Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. Eur J Heart Fail. 2017 04; 19(4):457-465.
    View in: PubMed
    Score: 0.053
  95. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996 Nov 01; 94(9):2285-96.
    View in: PubMed
    Score: 0.052
  96. Leary PJ, Tedford RJ, Bluemke DA, Bristow MR, Heckbert SR, Kawut SM, Krieger EV, Lima JA, Masri CS, Ralph DD, Shea S, Weiss NS, Kronmal RA. Histamine H2 Receptor Antagonists, Left?Ventricular Morphology, and Heart?Failure?Risk: The MESA Study. J Am Coll Cardiol. 2016 Apr 05; 67(13):1544-1552.
    View in: PubMed
    Score: 0.050
  97. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995 Jul; 16 Suppl F:20-31.
    View in: PubMed
    Score: 0.048
  98. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995 May; 25(6):1225-31.
    View in: PubMed
    Score: 0.047
  99. Vehlow C, Kao DP, Bristow MR, Hunter LE, Weiskopf D, G?rg C. Visual analysis of biological data-knowledge networks. BMC Bioinformatics. 2015 Apr 29; 16:135.
    View in: PubMed
    Score: 0.047
  100. Feldman AM, She L, McNamara DM, Mann DL, Bristow MR, Maisel AS, Wagner DR, Andersson B, Chiariello L, Hayward CS, Hendry P, Parker JD, Racine N, Selzman CH, Senni M, Stepinska J, Zembala M, Rouleau J, Velazquez EJ, Lee KL. Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials. Cardiology. 2015; 130(2):69-81.
    View in: PubMed
    Score: 0.046
  101. Abraham WT, Lowes BD, White M, Ferguson DA, Scheffel CA, Wolfel EE, Lindenfeld J, Bristow MR. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. J Card Fail. 1994 Oct; 1(1):57-62.
    View in: PubMed
    Score: 0.045
  102. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994 Jul-Aug; 13(4):S107-12.
    View in: PubMed
    Score: 0.045
  103. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation. 1994 Apr; 89(4):1632-42.
    View in: PubMed
    Score: 0.044
  104. Bristow MR, Lowes BD. Low-dose inotropic therapy for ambulatory heart failure. Coron Artery Dis. 1994 Feb; 5(2):112-8.
    View in: PubMed
    Score: 0.043
  105. Bristow MR. Use of oral enoximone in pharmacologic bridging to cardiac transplantation. Z Kardiol. 1994; 83 Suppl 2:15-9.
    View in: PubMed
    Score: 0.043
  106. Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman AM. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993 Dec; 92(6):2737-45.
    View in: PubMed
    Score: 0.043
  107. Le CH, Mulligan CM, Routh MA, Bouma GJ, Frye MA, Jeckel KM, Sparagna GC, Lynch JM, Moore RL, McCune SA, Bristow M, Zarini S, Murphy RC, Chicco AJ. Delta-6-desaturase links polyunsaturated fatty acid metabolism with phospholipid remodeling and disease progression in heart failure. Circ Heart Fail. 2014 Jan; 7(1):172-83.
    View in: PubMed
    Score: 0.043
  108. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 1993 Oct; 22(4 Suppl A):61A-71A.
    View in: PubMed
    Score: 0.042
  109. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart. Circulation. 1993 Aug; 88(2):472-80.
    View in: PubMed
    Score: 0.042
  110. Aleong RG, Sauer WH, Davis G, Murphy GA, Port JD, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, Bristow MR. Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013 Aug; 1(4):338-344.
    View in: PubMed
    Score: 0.042
  111. Kao DP, Wagner BD, Robertson AD, Bristow MR, Lowes BD. A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PLoS One. 2012; 7(11):e48184.
    View in: PubMed
    Score: 0.040
  112. O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh R, Nelson P, Medway A, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial pharmacogenetic interactions of bucindolol and ?1, a2C adrenergic receptor polymorphisms. PLoS One. 2012; 7(10):e44324.
    View in: PubMed
    Score: 0.040
  113. Kawut SM, Barr RG, Lima JA, Praestgaard A, Johnson WC, Chahal H, Ogunyankin KO, Bristow MR, Kizer JR, Tandri H, Bluemke DA. Right ventricular structure is associated with the risk of heart failure and cardiovascular death: the Multi-Ethnic Study of Atherosclerosis (MESA)--right ventricle study. Circulation. 2012 Oct 02; 126(14):1681-8.
    View in: PubMed
    Score: 0.039
  114. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992 Mar; 89(3):803-15.
    View in: PubMed
    Score: 0.038
  115. Anderson FL, Port JD, Reid BB, Hanson G, Kralios AC, Hershberger RE, Bristow MR. Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1992; 20(5):800-6.
    View in: PubMed
    Score: 0.038
  116. Feldman AM, Ray PE, Bristow MR. Expression of alpha-subunits of G proteins in failing human heart: a reappraisal utilizing quantitative polymerase chain reaction. J Mol Cell Cardiol. 1991 Dec; 23(12):1355-8.
    View in: PubMed
    Score: 0.037
  117. O'Connell JB, Gilbert EM, Renlund DG, Bristow MR. Enoximone as a bridge to heart transplantation: the Utah experience. J Heart Lung Transplant. 1991 May-Jun; 10(3):477-81.
    View in: PubMed
    Score: 0.036
  118. Hershberger RE, Feldman AM, Bristow MR. A1-adenosine receptor inhibition of adenylate cyclase in failing and nonfailing human ventricular myocardium. Circulation. 1991 Apr; 83(4):1343-51.
    View in: PubMed
    Score: 0.036
  119. Gilbert EM, O'Connell JB, Bristow MR. Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade. Heart Vessels Suppl. 1991; 6:29-39.
    View in: PubMed
    Score: 0.035
  120. Feiner EC, Chung P, Jasmin JF, Zhang J, Whitaker-Menezes D, Myers V, Song J, Feldman EW, Funakoshi H, Degeorge BR, Yelamarty RV, Koch WJ, Lisanti MP, McTiernan CF, Cheung JY, Bristow MR, Chan TO, Feldman AM. Left ventricular dysfunction in murine models of heart failure and in failing human heart is associated with a selective decrease in the expression of caveolin-3. J Card Fail. 2011 Mar; 17(3):253-63.
    View in: PubMed
    Score: 0.035
  121. Carson P, Fiuzat M, O'Connor C, Anand I, Plehn J, Lindenfeld JA, Silver M, White M, Miller A, Davis G, Robertson AD, Bristow M, Gottlieb S. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (?-Blocker Evaluation of Survival Trial [BEST]). Am Heart J. 2010 Oct; 160(4):649-54.
    View in: PubMed
    Score: 0.034
  122. Drakos SG, Kfoury AG, Hammond EH, Reid BB, Revelo MP, Rasmusson BY, Whitehead KJ, Salama ME, Selzman CH, Stehlik J, Clayson SE, Bristow MR, Renlund DG, Li DY. Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart. J Am Coll Cardiol. 2010 Jul 27; 56(5):382-91.
    View in: PubMed
    Score: 0.034
  123. Port JD, Gilbert EM, Larrabee P, Mealey P, Volkman K, Ginsburg R, Hershberger RE, Murray J, Bristow MR. Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart. Circulation. 1990 Mar; 81(3):929-38.
    View in: PubMed
    Score: 0.033
  124. Feldman AM, Bristow MR. The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy. Cardiology. 1990; 77 Suppl 1:1-32.
    View in: PubMed
    Score: 0.033
  125. Metra M, Eichhorn E, Abraham WT, Linseman J, B?hm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009 Dec; 30(24):3015-26.
    View in: PubMed
    Score: 0.032
  126. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett SB. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010 Jan; 3(1):21-8.
    View in: PubMed
    Score: 0.032
  127. Bristow MR, Port JD, Hershberger RE, Gilbert EM, Feldman AM. The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure. Eur Heart J. 1989 Jun; 10 Suppl B:45-54.
    View in: PubMed
    Score: 0.031
  128. O'Connell JB, Renlund DG, Bristow MR. Cardiac transplantation: emerging role of the internist/cardiologist. J Intern Med. 1989 Mar; 225(3):147-56.
    View in: PubMed
    Score: 0.031
  129. Taylor MR, Slavov D, Humphrey K, Zhao L, Cockroft J, Zhu X, Lavori P, Bristow MR, Mestroni L, Lazzeroni LC. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics. 2009 Jan; 19(1):35-43.
    View in: PubMed
    Score: 0.030
  130. MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb; 15(1):5-8.
    View in: PubMed
    Score: 0.030
  131. Bristow MR, Minobe W, Rasmussen R, Hershberger RE, Hoffman BB. Alpha-1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther. 1988 Dec; 247(3):1039-45.
    View in: PubMed
    Score: 0.030
  132. Bristow MR, Sandoval AB, Gilbert EM, Deisher T, Minobe W, Rasmussen R. Myocardial alpha- and beta-adrenergic receptors in heart failure: is cardiac-derived norepinephrine the regulatory signal? Eur Heart J. 1988 Jun; 9 Suppl H:35-40.
    View in: PubMed
    Score: 0.029
  133. Tate CW, Robertson AD, Zolty R, Shakar SF, Lindenfeld J, Wolfel EE, Bristow MR, Lowes BD. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). J Card Fail. 2007 Nov; 13(9):732-7.
    View in: PubMed
    Score: 0.028
  134. Lowes BD, Zolty R, Shakar SF, Brieke A, Gray N, Reed M, Calalb M, Minobe W, Lindenfeld J, Wolfel EE, Geraci M, Bristow MR, Cleveland J. Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers. J Heart Lung Transplant. 2007 Nov; 26(11):1170-6.
    View in: PubMed
    Score: 0.028
  135. Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J. 2007 Nov; 154(5):861-9.
    View in: PubMed
    Score: 0.028
  136. Sparagna GC, Chicco AJ, Murphy RC, Bristow MR, Johnson CA, Rees ML, Maxey ML, McCune SA, Moore RL. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J Lipid Res. 2007 Jul; 48(7):1559-70.
    View in: PubMed
    Score: 0.027
  137. Bristow MR, Ginsburg R, Gilbert EM, Hershberger RE. Heterogeneous regulatory changes in cell surface membrane receptors coupled to a positive inotropic response in the failing human heart. Basic Res Cardiol. 1987; 82 Suppl 2:369-76.
    View in: PubMed
    Score: 0.027
  138. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986 Dec; 74(6):1290-302.
    View in: PubMed
    Score: 0.026
  139. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep; 59(3):297-309.
    View in: PubMed
    Score: 0.026
  140. Taylor MR, Bristow MR. Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure. Novartis Found Symp. 2006; 274:73-83; discussion 83-9, 152-5, 272-6.
    View in: PubMed
    Score: 0.025
  141. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005 Dec; 11(9):693-9.
    View in: PubMed
    Score: 0.025
  142. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985 Jul; 17 Suppl 2:41-52.
    View in: PubMed
    Score: 0.024
  143. Fowler MB, Bristow MR. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol. 1985 Apr 26; 55(10):120D-124D.
    View in: PubMed
    Score: 0.024
  144. Domanski M, Fleg J, Bristow M, Knox S. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail. 2005 Mar; 11(2):83-6.
    View in: PubMed
    Score: 0.023
  145. Sucharov CC, Helmke SM, Langer SJ, Perryman MB, Bristow M, Leinwand L. The Ku protein complex interacts with YY1, is up-regulated in human heart failure, and represses alpha myosin heavy-chain gene expression. Mol Cell Biol. 2004 Oct; 24(19):8705-15.
    View in: PubMed
    Score: 0.023
  146. Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med. 1984 Sep 27; 311(13):850-1.
    View in: PubMed
    Score: 0.023
  147. Bristow MR. Myocardial beta-adrenergic receptor downregulation in heart failure. Int J Cardiol. 1984 May; 5(5):648-52.
    View in: PubMed
    Score: 0.022
  148. Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Simon M, Robertson AD, Bristow MR, Wolfel EE. Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers. J Card Fail. 2004 Feb; 10(1):15-20.
    View in: PubMed
    Score: 0.022
  149. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003 Sep 03; 42(5):914-22.
    View in: PubMed
    Score: 0.021
  150. Sucharov CC, Mariner P, Long C, Bristow M, Leinwand L. Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter. J Biol Chem. 2003 Aug 15; 278(33):31233-9.
    View in: PubMed
    Score: 0.021
  151. Ginsburg R, Esserman LJ, Bristow MR. Myocardial performance and extracellular ionized calcium in a severely failing human heart. Ann Intern Med. 1983 May; 98(5 Pt 1):603-6.
    View in: PubMed
    Score: 0.021
  152. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003 Feb 19; 289(7):871-8.
    View in: PubMed
    Score: 0.020
  153. Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002 Oct 02; 40(7):1248-58.
    View in: PubMed
    Score: 0.020
  154. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22; 307(4):205-11.
    View in: PubMed
    Score: 0.019
  155. Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer. 1982 Jul 01; 50(1):32-41.
    View in: PubMed
    Score: 0.019
  156. Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, Wright TJ. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002 Apr 16; 105(15):1797-803.
    View in: PubMed
    Score: 0.019
  157. Communal C, Colucci WS, Remondino A, Sawyer DB, Port JD, Wichman SE, Bristow MR, Singh K. Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. J Card Fail. 2002 Apr; 8(2):86-92.
    View in: PubMed
    Score: 0.019
  158. Leier CV, Silver MA, Rich MW, Eichhorn EJ, Fowler MB, Giles TD, Johnstone DE, Le Jemtel TH, Lachmann JS, Levine TB, Armstrong PW, Dec WG, Jessup M, Howlett J, Hershberger RE, Cohn JN, Adams KF, Colucci WS, Warner-Stevenson L, Hosenpud JD, Bristow MR, Pina I, Baughman KL, Binkley PF, Ventura HO, Francis GS, White M, Miller LW, Berry B, Missov E. Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment. Congest Heart Fail. 2002 Mar-Apr; 8(2):98-124.
    View in: PubMed
    Score: 0.019
  159. Lindenfeld J, Robertson AD, Lowes BD, Bristow MR. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. J Am Coll Cardiol. 2001 Dec; 38(7):1950-6.
    View in: PubMed
    Score: 0.019
  160. Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail. 2001 Jun; 7(2):114-21.
    View in: PubMed
    Score: 0.018
  161. Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail. 2001 Jun; 7(2 Suppl 1):8-12.
    View in: PubMed
    Score: 0.018
  162. Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001 05 31; 344(22):1659-67.
    View in: PubMed
    Score: 0.018
  163. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001 May 03; 344(18):1358-65.
    View in: PubMed
    Score: 0.018
  164. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol. 2001 May; 37(6):1692-9.
    View in: PubMed
    Score: 0.018
  165. Schleman KA, Lindenfeld JA, Lowes BD, Bristow MR, Ferguson D, Wolfel EE, Abraham WT, Zisman LS. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail. 2001 Mar; 7(1):4-12.
    View in: PubMed
    Score: 0.018
  166. Lindenfeld J, Lowes BD, Bristow MR. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol. Ann Pharmacother. 1999 Dec; 33(12):1266-9.
    View in: PubMed
    Score: 0.016
  167. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999 Apr 15; 83(8):1201-5.
    View in: PubMed
    Score: 0.016
  168. Bowling N, Walsh RA, Song G, Estridge T, Sandusky GE, Fouts RL, Mintze K, Pickard T, Roden R, Bristow MR, Sabbah HN, Mizrahi JL, Gromo G, King GL, Vlahos CJ. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation. 1999 Jan 26; 99(3):384-91.
    View in: PubMed
    Score: 0.015
  169. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998 Mar; 4(1):37-44.
    View in: PubMed
    Score: 0.014
  170. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997 Nov 01; 100(9):2315-24.
    View in: PubMed
    Score: 0.014
  171. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest. 1997 Nov 01; 100(9):2362-70.
    View in: PubMed
    Score: 0.014
  172. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail. 1997 Sep; 3(3):173-9.
    View in: PubMed
    Score: 0.014
  173. Cohn JN, Bristow MR, Chien KR, Colucci WS, Frazier OH, Leinwand LA, Lorell BH, Moss AJ, Sonnenblick EH, Walsh RA, Mockrin SC, Reinlib L. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation. 1997 Feb 18; 95(4):766-70.
    View in: PubMed
    Score: 0.013
  174. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23; 334(21):1349-55.
    View in: PubMed
    Score: 0.013
  175. Focaccio A, Peeters G, Movsesian M, Roden R, Eki Y, Krall J, Bristow MR. Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation. 1996 Feb 15; 93(4):817-25.
    View in: PubMed
    Score: 0.012
  176. Hunt SA, Bristow MR, Kubo SH, O'Connell JB, Young JB. Guidelines for training in adult cardiovascular medicine. Core Cardiology Training Symposium (COCATS). Task Force 8: training in heart failure and transplantation. J Am Coll Cardiol. 1995 Jan; 25(1):29-31.
    View in: PubMed
    Score: 0.012
  177. Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY, Renlund DG. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J. 1995 Jan; 129(1):197-9.
    View in: PubMed
    Score: 0.012
  178. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med. 1993 Jul 15; 329(3):149-55.
    View in: PubMed
    Score: 0.010
  179. Bristow MR, Larrabee P, M?ller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig. 1992; 70 Suppl 1:S105-13.
    View in: PubMed
    Score: 0.009
  180. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC. Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest. 1991 Jul; 88(1):15-9.
    View in: PubMed
    Score: 0.009
  181. Feldman AM, Cates AE, Bristow MR, Van Dop C. Altered expression of alpha-subunits of G proteins in failing human hearts. J Mol Cell Cardiol. 1989 Apr; 21(4):359-65.
    View in: PubMed
    Score: 0.008
  182. Gilbert EM, Bristow MR, Mason JW. Acute hemodynamic response to low dose enoximone (MDL 17,043): an oral dose-range study. Am J Cardiol. 1987 Aug 14; 60(5):57C-62C.
    View in: PubMed
    Score: 0.007
  183. Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR. Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review. Am J Med. 1986 Mar; 80(3):483-5.
    View in: PubMed
    Score: 0.006
  184. Carniel E, Taylor MR, Sinagra G, Di Lenarda A, Ku L, Fain PR, Boucek MM, Cavanaugh J, Miocic S, Slavov D, Graw SL, Feiger J, Zhu XZ, Dao D, Ferguson DA, Bristow MR, Mestroni L. Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation. 2005 Jul 05; 112(1):54-9.
    View in: PubMed
    Score: 0.006
  185. Bristow MR, Ginsburg R, Strosberg A, Montgomery W, Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest. 1984 Jul; 74(1):212-23.
    View in: PubMed
    Score: 0.006
  186. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983 Nov; 106(5 Pt 1):1048-56.
    View in: PubMed
    Score: 0.005
  187. Bristow MR. Toxic cardiomyopathy due to doxorubicin. Hosp Pract (Off Ed). 1982 Dec; 17(12):101-8, 110-1.
    View in: PubMed
    Score: 0.005
  188. Freeman K, Lerman I, Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ, Iaccarino G, Koch WJ, Leinwand LA. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001 Apr; 107(8):967-74.
    View in: PubMed
    Score: 0.004
  189. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978 Jun; 62(6):873-9.
    View in: PubMed
    Score: 0.004
  190. Pende A, Tremmel KD, DeMaria CT, Blaxall BC, Minobe WA, Sherman JA, Bisognano JD, Bristow MR, Brewer G, Port J. Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway. J Biol Chem. 1996 Apr 05; 271(14):8493-501.
    View in: PubMed
    Score: 0.003
  191. Renlund DG, Bristow MR, Burton NA, Jones KW, Karwande SV, Gay WA. Survival following cardiac transplantation--what are acceptable standards? West J Med. 1987 May; 146(5):627-30.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)